陈降化瘀胶囊治疗糖尿病脂肪肝临床观察

The clinical observation of Chenjianghuayu capsule in the theatment of diabetes mellitus with fatty liver

目的观察陈降化瘀胶囊治疗糖尿病脂肪肝的临床疗效。方法将2型糖尿病合并脂肪肝患者64例随机分为治疗组和对照组各32例。治疗组在常规降糖治疗基础上予陈降化瘀胶囊2.4g口服,每天3次;对照组在常规降糖治疗基础上加用血脂康2粒,每天2次。均2个月为1个疗程。检测2组肝脏B型超声,并比较2组空腹血糖(FBG)、餐后2h血糖(2h PG)、体质量指数(BMI)、胆固醇(TC)、三酰甘油(TG)及空腹胰岛素(FINS)水平。结果治疗组治疗后脂肪肝程度明显改善,且改善程度优于对照组,差异均有统计学意义(P<0.05)。治疗后,治疗组FBG、2h PG、BMI、TC、TG及FINS水平均下降,且BMI、TC、TG及FINS水平低于对照组,差异均有统计学意义(P<0.05);对照组仅FBG、2h PG水平较治疗前下降(P<0.05),其余指标比较差异均无统计学意义(P>0.05)。结论陈降化瘀胶囊对糖尿病脂肪肝具有较好的治疗作用。

Objective To observe the clinical effect of Chenjianghuayu capsule in the theatment of diabetes mellitus with fatty liver. Methods 64 cases patients with type 2 diabetes mellitus with fatty liver were randomly divided into treatment group and control group, each of 32 cases. On the basis of conventional antidiabetic therapy, treatment group were given Chen- jianghuayu capsule 2.4g orally ,3 times a day;Control group received Xuezhikang 2 capsules ,2 times a day. All two months of a course of treatment. Detected liver B-mode ultrasound of two groups, and compared the level of fasting blood glucose （FBG）, 2h postprandial blood glucose（2h PG） ,body mass index（BMI） ,cholesterol（TC） ,triglyceride（TG） and fasting insulin（FINS） of two groups. Results The degree of fatty liver in treatment group improved significantly, and the degree of improvement was more than that in control group, the difference was statistically significant（ P 〈 0.05 ）. After treatment, levels of FBG,2h pG, BMI, TC,TG and FINS in treatment group dropped, and the levels of BMI, TC, TG and FINS were lower than those in control group,the difference were statistically significance（ P 〈 0.05 ） ;In control group, after treatment only the levels of FBG,2h PG decreased（ P 〈 0.05 ） , and the remaining indicators compared, the difference were not statistically significant（ P 〉 0.05 ）. Conclusion Chenjianghuayu capsule in the theatment of diabetes mellitus with fatty liver has a better therapeutic effect.